Importance of the study of renal function in cardiology;Importancia del estudio de la función renal en cardiología

Medicina Clinica

Volumn 128, Issue 18, 2007, Pages 705-710

  Martín, Ana ^a   Cordero, Alberto ^a   Rodríguez, Moisés ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Heart failure; Ischaemic heart disease; Renal function

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIURETIC AGENT; TROPONIN;

ATHEROSCLEROSIS; BLEEDING; CLINICAL FEATURE; CLINICAL PRACTICE; DIABETES MELLITUS; DIAGNOSTIC PROCEDURE; GLOMERULUS FILTRATION; HEART DISEASE; HEART FAILURE; HEART MUSCLE ISCHEMIA; HOSPITALIZATION; HUMAN; HYPERTENSION; INCIDENCE; KIDNEY FAILURE; KIDNEY FUNCTION; MORTALITY; PRIMARY PREVENTION; PROPHYLAXIS; REVIEW; RISK FACTOR;

EID: 34347204095     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13102352     Document Type: Review

References (49)

1. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation. 2001;104:2746-53.
2. Llácer A, Fernández-Cuenca R. Mortalidad en España en 1999 y 2000. (II). Boletín Epidemiológico Semanal. 2003;11:121-32.
3. Rodríguez Artalejo F, López García E, Gutiérrez-Fisac JL, Banegas Banegas JR, Lafuente Urdinguio PJ, Domínguez Rojas V. La transición de la cardiopatía isquémica aguda a crónica en España, 1980-1994. Prev Med. 2002;34:72-81.
4. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296-305.
5. Henry RM, Kostense PJ, Bos G, Dekker JM, Nijpels G, Heine RJ, et al. Mild renal insufficiency is associated with increased cardiovascular mortality: The Hoorn Study. Kidney Int. 2002;62:1402-7.
6. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med. 2001;134:629-36.
7. Parfrey PS, Foley RN. The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol. 1999;10:1606-15.
8. Fried LP, Kronmal RA, Newman AB, Bild DE, Mittelmark MB, Polak JF, et al. Risk factors for 5-year mortality in older adults: the Cardiovascular Health Study. JAMA. 1998;279:585-92.
9. Cordero A, Laclaustra M, Leon M, Casasnovas JA, Grima A, Najar M, et al. Factores de riesgo cardiovascular y síndrome metabólico asociados con la disfunción renal subclínica. Med Clin (Barc) 2005;125:653-8.
10. Silverberg D, Wexler D, Blum M, Schwartz D, Laina A. The association between congestive heart failure and chronic renal disease. Curr Opin Nephrol Hypertens. 2004;13:163-70.
11. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366:895-906.
12. Rahman M, Pressel S, Davis BR, Nwachuku C, Wright JT Jr, Whelton PK, et al. Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. Ann Intern Med. 2006;144:172-80.
13. Rahman M, Pressel S, Davis BR, Nwachuku C, Wright JT Jr, Whelton PK, et al. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2005;165:936-46.
14. Davis BR, Piller LB, Cutler JA, Furberg C, Dunn K, Franklin S, et al. Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Circulation. 2006;113:2201-10.
15. Ohman EM, Armstrong PW, Christenson RH, Granger CB, Katus HA, Hamm CW, et al. Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators. N Engl J Med. 1996;335:1333-41.
16. Gibler WB, Cannon CP, Blomkalns AL, Char DM, Drew BJ, Hollander JE, et al. Practical implementation of the guidelines for unstable angina/non-ST- segment elevation myocardial infarction in the emergency department: a scientific statement from the American Heart Association Council on Clinical Cardiology (Subcommittee on Acute Cardiac Care), Council on Cardiovascular Nursing, and Quality of Care and Outcomes Research Interdisciplinary Working Group, in Collaboration With the Society of Chest Pain Centers. Circulation. 2005;111:2699-710.
17. Van Lente F, McErlean ES, DeLuca SA, Peacock WF, Rao JS, Nissen SE. Ability of troponins to predict adverse outcomes in patients with renal insufficiency and suspected acute coronary syndromes: a case-matched study. J Am Coll Cardiol. 1999;33:471-8.
18. Aviles RJ, Askari AT, Lindahl B, Wallentin L, Jia G, Ohman EM, et al. Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction. N Engl J Med. 2002;346:2047-52.
19. Kontos MC, Garg R, Anderson FP, Tatum JL, Ornato JP, Jesse RL. Outcomes in patients admitted for chest pain with renal failure and troponin I elevations. Am Heart J. 2005;150:674-80.
20. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004;351:1285-95.
21. Sorensen CR, Brendorp B, Rask-Madsen C, Kober L, Kjoller E, Torp-Pedersen C. The prognostic importance of creatinine clearance after acute myocardial infarction. Eur Heart J. 2002;23:948-52.
22. Gibson CM, Dumaine RL, Gelfand EV, Murphy SA, Morrow DA, Wiviott SD, et al. Association of glomerular filtration rate on presentation with subsequent mortality in non-ST-segment elevation acute coronary syndrome; observations in 13,307 patients in five TIMI trials. Eur Heart J. 2004;25:1998-2005.
23. Dumaine R, Collet JP, Tanguy ML, Mansencal N, Dubois-Rande JL, Henry P, et al. Prognostic significance of renal insufficiency in patients presenting with acute coronary syndrome (the Prospective Multicenter SYCOMORE study). Am J Cardiol. 2004;94:1543-7.
24. Blackman DJ, Pinto R, Ross JR, Seidelin PH, Ing D, Jackevicius C, et al. Impact of renal insufficiency on outcome after contemporary percutaneous coronary intervention. Am Heart J. 2006;151:146-52.
25. Best PJ, Lennon R, Ting HH, Bell MR, Rihal CS, Holmes DR, et al. The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol. 2002;39:1113-9.
26. Facila L, Núnez J, Bodi V, Sanchis J, Bertomeu-Gonzalez V, Consuegra L, et al. Valor pronóstico de la creatinina sérica en el síndrome coronario agudo sin elevación del segmento ST. Rev Esp Cardiol. 2006;59:209-16.
27. Hillege HL, Van Gilst WH, Van Veldhuisen DJ, Navis G, Grobbee DE, De Graeff PA, et al. Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibition: the CATS randomized trial. Eur Heart J. 2003;24:412-20.
28. Goldberg A, Hammerman H, Petcherski S, Zdorovyak A, Yalonetsky S, Kapeliovich M, et al. Inhospital and 1-year mortality of patients who develop worsening renal function following acute ST-elevation myocardial infarction. Am Heart J. 2005;150:330-7.
29. Hillis GS, Croal BL, Buchan KG, El-Shafei H, Gibson G, Jeffrey RR, et al. Renal function and outcome from coronary artery bypass grafting: impact on mortality after a 2.3-year follow-up. Circulation. 2006;113:1056-62.
30. Cooper WA, O'Brien SM, Thourani VH, Guyton RA, Bridges CR, Szczech LA, et al. Impact of renal dysfunction on outcomes of coronary artery bypass surgery: results from the Society of Thoracic Surgeons National Adult Cardiac Database. Circulation. 2006;113:1063-70.
31. Perry HM Jr, Miller JP, Fornoff JR, Baty JD, Sambhi MP, Rutan G, et al. Early predictors of 15-year end-stage renal disease in hypertensive patients. Hypertension. 1995;25:587-94.
32. Caramelo C, Gil P. Combined Cardio-Renal Failure: a Key Factor in Heart Failure Progression and Therapy. Rev Esp Cardiol. 2006;59:87-90.
33. Iaina A, Silverberg DS, Wexler D. Therapy insight: congestive heart failure, chronic kidney disease and anemia, the cardio-renal-anemia syndrome. Nat Clin Pract Cardiovasc Med. 2005;2:95-100.
34. Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol. 2000;35:681-9.
35. Hillege H, Van Gilst W, De Zeeuw D, Van Veldhuisen DJ. Renal function as a predictor of prognosis in chronic heart failure. Heart Fail Monit. 2002;2:78-84.
36. Obrador GT, Pereira BJ. Systemic complications of chronic kidney disease. Pinpointing clinical manifestations and best management. Postgrad Med. 2002;111:115-22; quiz 21.
37. Grigorian Shamagian L, Varela Roman A, Pedreira Pérez M, Gómez Otero I, Virgos Lamela A, González-Juanatey JR. La insuficiencia renal es un predictor independiente de la mortalidad en pacientes hospitalizados por IC y se asocia con un peor perfil de riesgo cardiovascular. Rev Esp Cardiol. 2006;59:99-108.
38. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429-35.
39. Bibbins-Domingo K, Lin F, Vittinghoff E, Barrett-Connor E, Grady D, Shlipak MG. Renal insufficiency as an independent predictor of mortality among women with heart failure. J Am Coll Cardiol. 2004;44:1593-600.
40. Knight EL, Glynn RJ, McIntyre KM, Mogun H, Avorn J. Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD). Am Heart J. 1999;138:849-55.
41. Erdmann E, Lechat P, Verkenne P, Wiemann H. Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure. Eur J Heart Fail. 2001;3:469-79.
42. Cice G, Ferrara L, D'Andrea A, D'Isa S, Di Benedetto A, Cittadini A, et al. Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol. 2003;41:1438-44.
43. Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002;106:2194-9.
44. Abdallah JG, Schrier RW, Edelstein C, Jennings SD, Wyse B, Ellison DH. Loop diuretic infusion increases thiazide-sensitive Na(+)/Cl(-)-cotransporter abundance: role of aldosterone. J Am Soc Nephrol. 2001;12:1335-41.
45. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362:759-66.
46. Shlipak MG, Smith GL, Rathore SS, Massie BM, Krumholz HM. Renal function, digoxin therapy, and heart failure outcomes: evidence from the digoxin intervention group trial. J Am Soc Nephrol. 2004;15:2195-203.
47. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539-49.
48. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Pérez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-17.
49. Pitt B, Remme W, Zannad F, Neaton J, Martínez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-21.